Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential vs Concomitant Docetaxel and Capecitabine in Early Breast Cancer
NCT00415285Phase 2Unknown
- Sponsor
- Georgia CORE
- Start
- Dec 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, capecitabine in breast cancer, sponsored by Georgia CORE. Status: unknown.
02
Drugs
docetaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00415285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00415285.